Why Aridis Pharmaceuticals Shares Are Soaring Today

Benzinga · 03/13 21:15

Aridis Pharmaceuticals Inc (NASDAQ:ARDS) announced preliminary topline results from the Phase 2a study of AR-501 in cystic fibrosis (CF) patients with confirmed Pseudomonas aeruginosa bacterial and other potential infections. The study evaluated the safety and pharmacokinetics of three ascending doses of AR-501 administered as an inhaled aerosol and was conducted with funding support from the Cystic Fibrosis Foundation. AR-501 is being developed as a once-per-week inhaled dosing regimen self-administered using a commercially available nebulizer device.Also Read: Aridis' Inhaled Pan-Coronavirus Antibody Cocktail Shows Encouraging Preclinical Action.The study's primary and secondary safety and pharmacokinetics (

View Full Text on the app

Risk disclosure: The above content only represents the opinion of the authors or guests, and does not represent any positions of Futu or constitute any investment advice on the part of Futu. Before making any investment decision, investors should consider the risk factors related to investment products based on their own circumstances and consult professional investment advisers where necessary. Futu makes every effort to verify the authenticity, accuracy, and originality of the above content, but does not make any guarantees or promises.